NASDAQ:HOLX - Hologic Stock Price, Price Target & More

$38.51 -0.65 (-1.66 %)
(As of 04/19/2018 01:18 PM ET)
Previous Close$39.16
Today's Range$38.36 - $39.16
52-Week Range$35.33 - $46.80
Volume597,300 shs
Average Volume2.61 million shs
Market Capitalization$10.69 billion
P/E Ratio18.93
Dividend YieldN/A

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.87%
Current Ratio1.25%
Quick Ratio0.98%


Trailing P/E Ratio18.93
Forward P/E Ratio17.12
P/E Growth1.74

Sales & Book Value

Annual Sales$3.06 billion
Price / Sales3.48
Cash Flow$3.6502 per share
Price / Cash10.55
Book Value$9.93 per share
Price / Book3.88


EPS (Most Recent Fiscal Year)$2.03
Net Income$755.50 million
Net Margins34.53%
Return on Equity20.07%
Return on Assets7.11%


Outstanding Shares276,530,000

How to Become a New Pot Stock Millionaire

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic (NASDAQ:HOLX) issued its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The medical equipment provider had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 EPS. View Hologic's Earnings History.

When is Hologic's next earnings date?

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its second quarter earnings guidance on Thursday, February, 8th. The company provided EPS guidance of $0.53-0.54 for the period, compared to the Thomson Reuters consensus estimate of $0.55. The company issued revenue guidance of $770-785, compared to the consensus revenue estimate of $790.90 million.

What price target have analysts set for HOLX?

13 Wall Street analysts have issued 1 year price targets for Hologic's stock. Their forecasts range from $42.00 to $52.00. On average, they anticipate Hologic's share price to reach $47.5385 in the next twelve months. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:
  • 1. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming the broader industry. The company's  blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover,  growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (3/6/2018)
  • 2. Needham & Company LLC analysts commented, "HOLX’s F1Q18 revenue was consistent with its 1/8/18 preannouncement while its EPS beat consensus. Management reiterated its FY18 revenue guidance and raised its EPS guidance due to tax reform. We note that HOLX expects to reinvest about half of its tax savings in marketing campaigns and R&D. HOLX’s organic revenue growth increased to 4.9% (adjusted for selling days) in F1Q18 from 4.4% in F4Q17. Breast Health growth improved from last quarter driven by the stronger international sales while Diagnostics growth (excluding the Blood divestiture) slowed. We expect HOLX’s revenue growth to accelerate as its Aesthetics business returns to Y/Y growth and it faces easier comps and we reiterate our Buy rating." (2/9/2018)

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:
  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • Robert W. McMahon, Chief Financial Officer (Age 49)
  • Peter J. Valenti III, Division President- Breast and Skeletal Health (Age 54)
  • Thomas A. West, Division President- Diagnostics (Age 53)
  • Allison P. Bebo, Senior Vice President - Human Resources (Age 49)
  • Michael J. Watts, Vice President, IR Contact Officer
  • John M. Griffin, General Counsel (Age 57)
  • Sally W. Crawford, Lead Independent Director (Age 64)
  • Charles J. Dockendorff, Director (Age 63)
  • Namal Nawana, Director (Age 47)

Has Hologic been receiving favorable news coverage?

Media headlines about HOLX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hologic earned a news sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 45.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $38.52.

How big of a company is Hologic?

Hologic has a market capitalization of $10.69 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  595 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  997
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hologic (NASDAQ:HOLX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Hologic in the last 12 months. Their average twelve-month price target is $47.5385, suggesting that the stock has a possible upside of 23.44%. The high price target for HOLX is $52.00 and the low price target for HOLX is $42.00. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.792.862.69
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.5385$48.3571$48.7857$47.7692
Price Target Upside: 23.44% upside28.10% upside11.26% upside29.49% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Goldman SachsSet Price TargetBuy$43.00LowView Rating Details
2/9/2018Canaccord GenuityReiterated RatingBuy$48.00LowView Rating Details
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00HighView Rating Details
2/9/2018Needham & Company LLCReiterated RatingBuy$50.00HighView Rating Details
2/9/2018Stifel NicolausDowngradeBuy -> Hold$45.00 -> $42.00HighView Rating Details
1/19/2018Deutsche BankDowngradeBuy -> Hold$49.00MediumView Rating Details
1/4/2018Bank of AmericaUpgradeNeutral -> Buy$50.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform -> Outperform$50.00MediumView Rating Details
12/20/2017CowenUpgradeBuy$52.00LowView Rating Details
11/9/2017Piper JaffrayReiterated RatingBuy$48.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$49.00 -> $44.00N/AView Rating Details
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 -> $51.00LowView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
7/17/2016UBSReiterated RatingBuy$45.00N/AView Rating Details
(Data available from 4/19/2016 forward)


Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.14
2019 EPS Consensus Estimate: $2.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.49$0.52$0.50
Q2 20183$0.51$0.52$0.52
Q3 20183$0.54$0.57$0.56
Q4 20183$0.53$0.60$0.56
Q1 20191$0.60$0.60$0.60
Q2 20191$0.60$0.60$0.60
Q3 20191$0.65$0.65$0.65
Q4 20191$0.65$0.65$0.65

Hologic (NASDAQ HOLX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$0.53N/AView Earnings Details
2/8/2018Q1 2018$0.50$0.55$785.80 million$791.10 millionViewListenView Earnings Details
11/8/2017Q4 2017$0.49$0.50$792.54 million$802.90 millionViewN/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
11/8/2010Q4 2010$0.30$0.30ViewN/AView Earnings Details
8/2/2010Q3 2010$0.29$0.30ViewN/AView Earnings Details
5/3/2010Q2 2010$0.29$0.29ViewN/AView Earnings Details
2/1/2010Q1 2010$0.26$0.29ViewN/AView Earnings Details
11/9/2009Q4 2009$0.26$0.28ViewN/AView Earnings Details
8/3/2009Q3 2009$0.26$0.29ViewN/AView Earnings Details
5/4/2009Q2 2009$0.27$0.29ViewN/AView Earnings Details
2/2/2009Q1 2009$0.30$0.31ViewN/AView Earnings Details
11/11/2008Q4 2008$0.30$0.30ViewN/AView Earnings Details
7/30/2008Q3 2008$0.29$0.33ViewN/AView Earnings Details
5/1/2008Q2 2008$0.28$0.29ViewN/AView Earnings Details
1/31/2008Q1 2008$0.23$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Hologic (NASDAQ:HOLX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 97.51%
Insider Trading History for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Allison P. BeboSVPSell7,000$38.75$271,250.00View SEC Filing  
3/15/2018Charles J DockendorffDirectorBuy13,000$38.80$504,400.00View SEC Filing  
2/13/2018Namal NawanaDirectorBuy6,600$37.88$250,008.006,954View SEC Filing  
11/20/2017Karleen Marie ObertonVPSell1,023$39.84$40,756.32View SEC Filing  
11/13/2017Elaine UllianDirectorSell9,282$40.50$375,921.00View SEC Filing  
11/8/2017Karleen Marie ObertonVPSell1,256$39.29$49,348.249,406View SEC Filing  
11/6/2017Karleen Marie ObertonVPSell538$39.40$21,197.208,343View SEC Filing  
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.2423,810View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.7223,810View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.4045,634View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.6223,810View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.2020,994View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.4946,206View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.8043,165View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.5840,577View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.0038,832View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.0437,377View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00157,305View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.6425,839View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.6524,596View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.6023,810View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00152,305View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.4236,798View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.3613,260View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.0510,859View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.889,065View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.669,839View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.6842,898View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.0017,005View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.0067,140View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.8455,053View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.5423,257View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.269,023View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.6031,157View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.808,819View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.5020,983View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.003,914View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.003,914View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.0039,215View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.2039,215View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.8039,215View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.321,500View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00815,306View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00815,306View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.6811,341View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00122View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00815,306View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.0314,470View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00237,500View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00198,900View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.9011,341View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00825,891View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.0019,090View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.4027,749View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00825,891View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.005,052View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.2820,632View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)


Hologic (NASDAQ HOLX) News Headlines

Traders Buy Large Volume of Call Options on Hologic (HOLX)Traders Buy Large Volume of Call Options on Hologic (HOLX) - April 19 at 8:32 AM
Check Cap (CHEK) & Hologic (HOLX) Critical ReviewCheck Cap (CHEK) & Hologic (HOLX) Critical Review - April 18 at 11:08 PM
4 MedTech Stocks to Keep in Good Books This Earnings Season4 MedTech Stocks to Keep in Good Books This Earnings Season - April 18 at 5:17 PM
Reviewing Check Cap (CHEK) & Hologic (HOLX)Reviewing Check Cap (CHEK) & Hologic (HOLX) - April 18 at 3:26 PM
$0.53 Earnings Per Share Expected for Hologic (HOLX) This Quarter$0.53 Earnings Per Share Expected for Hologic (HOLX) This Quarter - April 18 at 3:08 PM
Hologic (HOLX) Upgraded to Sell at BidaskClubHologic (HOLX) Upgraded to Sell at BidaskClub - April 18 at 10:05 AM
Goldman Remains Positive on Hologic (HOLX)Goldman Remains Positive on Hologic (HOLX) - April 18 at 8:50 AM
Hologic (HOLX) PT Set at $43.00 by Goldman SachsHologic (HOLX) PT Set at $43.00 by Goldman Sachs - April 18 at 8:37 AM
BidaskClub Lowers Hologic (HOLX) to BuyBidaskClub Lowers Hologic (HOLX) to Buy - April 16 at 9:49 AM
Check Cap (CHEK) vs. Hologic (HOLX) Critical AnalysisCheck Cap (CHEK) vs. Hologic (HOLX) Critical Analysis - April 15 at 3:25 AM
Hologic (HOLX) Downgraded by BidaskClubHologic (HOLX) Downgraded by BidaskClub - April 14 at 12:49 AM
Hologic (HOLX) Price Target Cut to $45.00Hologic (HOLX) Price Target Cut to $45.00 - April 13 at 7:51 PM
Hologic (HOLX) Price Target Cut to $49.00Hologic (HOLX) Price Target Cut to $49.00 - April 13 at 3:16 PM
Hologics (HOLX) Sector Perform Rating Reaffirmed at Royal Bank of CanadaHologic's (HOLX) Sector Perform Rating Reaffirmed at Royal Bank of Canada - April 12 at 3:58 PM
Hologic (HOLX) Earns "Equal Weight" Rating from BarclaysHologic (HOLX) Earns "Equal Weight" Rating from Barclays - April 12 at 3:27 PM
Edited Transcript of HOLX presentation 6-Mar-17 9:35pm GMTEdited Transcript of HOLX presentation 6-Mar-17 9:35pm GMT - April 12 at 9:29 AM
Hologic (HOLX) Rating Lowered to Sell at BidaskClubHologic (HOLX) Rating Lowered to Sell at BidaskClub - April 11 at 9:30 PM
Reviewing Hologic (HOLX) & Check Cap (CHEK)Reviewing Hologic (HOLX) & Check Cap (CHEK) - April 10 at 1:41 AM
Hologic Looks Iffy For NowHologic Looks Iffy For Now - April 8 at 5:24 PM
Financial Comparison: Check Cap (CHEK) vs. Hologic (HOLX)Financial Comparison: Check Cap (CHEK) vs. Hologic (HOLX) - April 7 at 11:15 PM
Analyzing Hologic (HOLX) & Check Cap (CHEK)Analyzing Hologic (HOLX) & Check Cap (CHEK) - April 7 at 12:18 AM
Wall Street Largely Bullish on Hologic Stock in MarchWall Street Largely Bullish on Hologic Stock in March - April 4 at 3:47 PM
Can HOLX Stock Rebound from Its Recent Lows?Can HOLX Stock Rebound from Its Recent Lows? - April 4 at 3:47 PM
Hologic’s Viera Expected to Be Key Growth Driver for 2018Hologic’s Viera Expected to Be Key Growth Driver for 2018 - April 4 at 8:52 AM
Hologic and Dexalytics Partner to Develop Software for AthletesHologic and Dexalytics Partner to Develop Software for Athletes - April 4 at 8:52 AM
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2018 on Wednesday, May 2, 2018Hologic to Announce Financial Results for the Second Quarter of Fiscal 2018 on Wednesday, May 2, 2018 - April 3 at 5:03 PM
Hologic (HOLX) Expected to Post Quarterly Sales of $780.06 MillionHologic (HOLX) Expected to Post Quarterly Sales of $780.06 Million - April 3 at 3:21 AM
 Brokerages Anticipate Hologic (HOLX) to Announce $0.53 EPS Brokerages Anticipate Hologic (HOLX) to Announce $0.53 EPS - April 1 at 3:17 PM
Hologic (HOLX) Receives Average Recommendation of "Buy" from BrokeragesHologic (HOLX) Receives Average Recommendation of "Buy" from Brokerages - April 1 at 8:16 AM
Hologic (HOLX) vs. Essilor International (ESLOY) Critical ContrastHologic (HOLX) vs. Essilor International (ESLOY) Critical Contrast - March 31 at 9:10 AM
Evercore ISI Initiates Coverage on Hologic (HOLX)Evercore ISI Initiates Coverage on Hologic (HOLX) - March 30 at 11:43 PM
Hologic (HOLX) Upgraded by Bank of America to "Buy"Hologic (HOLX) Upgraded by Bank of America to "Buy" - March 30 at 5:08 PM
Hologic's Clarity HD & Intelligent 2D Systems Gain FDA NodHologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod - March 29 at 9:02 AM
Hologic Forecasted to Earn FY2020 Earnings of $2.89 Per Share (HOLX)Hologic Forecasted to Earn FY2020 Earnings of $2.89 Per Share (HOLX) - March 29 at 8:46 AM
Hologics Clarity HD & Intelligent 2D Systems Gain FDA NodHologic's Clarity HD & Intelligent 2D Systems Gain FDA Nod - March 28 at 4:56 PM
Piper Jaffray Remains Bullish on Hologic (HOLX)Piper Jaffray Remains Bullish on Hologic (HOLX) - March 28 at 9:03 AM
Hologic (HOLX) Reports FDA Approval of New Innovations on its 3Dimensions Mammography SystemHologic (HOLX) Reports FDA Approval of New Innovations on its 3Dimensions Mammography System - March 27 at 9:07 AM
FDA Approves New Innovations on Hologics 3Dimensions™ Mammography System, the Fastest, Highest Resolution Breast Tomosynthesis System Ever(1)FDA Approves New Innovations on Hologic's 3Dimensions™ Mammography System, the Fastest, Highest Resolution Breast Tomosynthesis System Ever(1) - March 27 at 8:12 AM
Hologic (HOLX) Lowered to Buy at Goldman SachsHologic (HOLX) Lowered to Buy at Goldman Sachs - March 26 at 9:15 AM
Should Value Investors Consider Hologic (HOLX) Stock Now?Should Value Investors Consider Hologic (HOLX) Stock Now? - March 23 at 5:10 PM
Insider Selling: Hologic, Inc. (HOLX) SVP Sells 7,000 Shares of StockInsider Selling: Hologic, Inc. (HOLX) SVP Sells 7,000 Shares of Stock - March 20 at 7:50 PM
Hologic, Inc. (HOLX) Expected to Earn Q1 2019 Earnings of $0.60 Per ShareHologic, Inc. (HOLX) Expected to Earn Q1 2019 Earnings of $0.60 Per Share - March 20 at 11:12 AM
$779.91 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter$779.91 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter - March 17 at 4:46 AM
Hologic, Inc. (HOLX) Director Acquires $504,400.00 in StockHologic, Inc. (HOLX) Director Acquires $504,400.00 in Stock - March 16 at 7:52 PM
Commit To Purchase Hologic At $30, Earn 5.8% Using Options - NasdaqCommit To Purchase Hologic At $30, Earn 5.8% Using Options - Nasdaq - March 16 at 6:01 PM
Appeals court hands win to Smith & Nephew in Hologic patent caseAppeals court hands win to Smith & Nephew in Hologic patent case - March 16 at 8:57 AM
Hologic (HOLX) Down 4.5% Since Earnings Report: Can It Rebound?Hologic (HOLX) Down 4.5% Since Earnings Report: Can It Rebound? - March 12 at 12:09 PM
"Dancing with the Stars" host and cervical cancer survivor Erin Andrews fights to save lives"Dancing with the Stars" host and cervical cancer survivor Erin Andrews fights to save lives - March 8 at 8:58 AM
Hologic, Inc. (HOLX) Given Average Recommendation of "Buy" by BrokeragesHologic, Inc. (HOLX) Given Average Recommendation of "Buy" by Brokerages - March 7 at 11:44 AM
Hologic (HOLX) Presents At Raymond James 39th Annual Institutional Investors Conference - SlideshowHologic (HOLX) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow - March 6 at 5:17 PM

SEC Filings

Hologic (NASDAQ:HOLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement


Hologic (NASDAQ HOLX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.